Technical Analysis for INZY - Inozyme Pharma, Inc.

Grade Last Price % Change Price Change
F 2.74 -1.76% -0.05
INZY closed down 0.71 percent on Wednesday, November 20, 2024, on 1.44 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -1.76%
Doji - Bullish? Reversal -1.76%
Lower Bollinger Band Walk Weakness -1.76%
New 52 Week Low Weakness -1.76%
Wide Bands Range Expansion -1.76%
Down 3 Days in a Row Weakness -1.76%
Down 4 Days in a Row Weakness -1.76%
Down 5 Days in a Row Weakness -1.76%
Oversold Stochastic Weakness -1.76%
New 52 Week Closing Low Bearish -2.46%

   Recent Intraday Alerts

Alert Time
Lower Bollinger Band Support about 1 hour ago
Down 5% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
New 52 Week Low about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna

Is INZY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.795
52 Week Low 2.69
Average Volume 272,814
200-Day Moving Average 5.11
50-Day Moving Average 4.79
20-Day Moving Average 3.97
10-Day Moving Average 3.45
Average True Range 0.27
RSI (14) 16.67
ADX 35.93
+DI 8.96
-DI 44.60
Chandelier Exit (Long, 3 ATRs) 4.46
Chandelier Exit (Short, 3 ATRs) 3.51
Upper Bollinger Bands 5.29
Lower Bollinger Band 2.66
Percent B (%b) 0.05
BandWidth 66.26
MACD Line -0.55
MACD Signal Line -0.42
MACD Histogram -0.1246
Fundamentals Value
Market Cap 172.31 Million
Num Shares 61.8 Million
EPS -1.44
Price-to-Earnings (P/E) Ratio -1.94
Price-to-Sales 0.00
Price-to-Book 2.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.07
Resistance 3 (R3) 3.07 2.97 3.03
Resistance 2 (R2) 2.97 2.90 2.98 3.01
Resistance 1 (R1) 2.88 2.86 2.88 2.88 2.99
Pivot Point 2.79 2.79 2.79 2.79 2.79
Support 1 (S1) 2.69 2.71 2.70 2.70 2.59
Support 2 (S2) 2.60 2.67 2.60 2.57
Support 3 (S3) 2.51 2.60 2.56
Support 4 (S4) 2.51